BLEXTEN DIN 02561514
Health Canada record
| Active ingredient(s) | BILASTINE 6 MG |
|---|---|
| Dosage form | Solution |
| Route | Ophthalmic |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | S01GX13 BILASTINE |
| Original market date | |
| Current status date | 01-Oct-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
Aralez Pharmaceuticals Canada Inc. — licence 3-002529, currently licensed, last inspection rating C (2024-05-01).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing BILASTINE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02570521 | APO- BILASTINE | APOTEX INC | Tablet | BILASTINE 20 MG | Approved |
| 02549867 | APO-BILASTINE ORAL SOLUTION | APOTEX INC | Solution | BILASTINE 2.5 MG | Approved |
| 02549875 | APO-BILASTINE ORODISPERSIBLE TABLETS | APOTEX INC | Tablet (Orally-Disintegrating) | BILASTINE 10 MG | Approved |
| 02549883 | APO-BILASTINE TABLETS | APOTEX INC | Tablet | BILASTINE 20 MG | Marketed |
| 02541556 | AURO-BILASTINE | AURO PHARMA INC | Tablet | BILASTINE 20 MG | Marketed |
| 02454130 | BLEXTEN | ARALEZ PHARMACEUTICALS CANADA INC | Tablet | BILASTINE 20 MG | Marketed |
| 02519038 | BLEXTEN | ARALEZ PHARMACEUTICALS CANADA INC | Tablet (Orally-Disintegrating) | BILASTINE 10 MG | Marketed |
| 02519011 | BLEXTEN | ARALEZ PHARMACEUTICALS CANADA INC | Solution | BILASTINE 2.5 MG | Marketed |
| 02544369 | GLN-BILASTINE | GLENMARK PHARMACEUTICALS CANADA INC. | Tablet | BILASTINE 20 MG | Marketed |
| 02546795 | JAMP BILASTINE | JAMP PHARMA CORPORATION | Tablet | BILASTINE 20 MG | Marketed |
| 02448262 | JAMP BILASTINE ORAL SOLUTION | JAMP PHARMA CORPORATION | Solution | BILASTINE 2.5 MG | Marketed |
| 02548410 | M-BILASTINE | MANTRA PHARMA INC | Tablet | BILASTINE 20 MG | Marketed |
| 02547279 | MAR-BILASTINE | MARCAN PHARMACEUTICALS INC | Tablet | BILASTINE 20 MG | Marketed |
| 02568772 | MINT-BILASTINE | MINT PHARMACEUTICALS INC | Tablet | BILASTINE 20 MG | Approved |
| 02551934 | NRA-BILASTINE | NORA PHARMA INC | Tablet | BILASTINE 20 MG | Marketed |
| 02561565 | PMS-BILASTINE | PHARMASCIENCE INC | Tablet | BILASTINE 20 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36097 | 2025-10-01 | Supplement to a New Drug Submission (SNDS) | Addition of new indication: the treatment of ocular signs and symptoms of seasonal and perennial allergic conjunctivitis in adults. Addition of new route of administration: Ophthalmic. Addition of new dosage form: Ophthalmic solution. New package labels. New package insert |
International API supply for BILASTINE
13 active FDA Drug Master Files.
Request a quote for BLEXTEN